由辉瑞一手孵化，现在拟被默克收购

生物制药小编2025-04-28

不出意外，SpringWorks Therapeutics要被德国默克收购了。近日，两家公司已就收购价上达成一致，德国默克将以每股47美元收购SpringWorks，收购总价约为35亿美元，如果后续收购工作顺利，该交易将在下周内完成。由辉瑞一手孵化SpringWorks成立于2017年，是一家专注于癌症和罕见病药物开发的Biotech公司，2019年在纳斯达克证券交易所上市。SpringWorks...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531294179?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-28 09:20","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2531294179","market":"us","top_or_hot":-1,"title":"由辉瑞一手孵化，现在拟被默克收购","media":"生物制药小编","content":"<div>\n<p>不出意外，SpringWorks Therapeutics要被德国默克收购了。近日，两家公司已就收购价上达成一致，德国默克将以每股47美元收购SpringWorks，收购总价约为35亿美元，如果后续收购工作顺利，该交易将在下周内完成。由辉瑞一手孵化SpringWorks成立于2017年，是一家专注于癌症和罕见病药物开发的Biotech公司，2019年在纳斯达克证券交易所上市。SpringWorks...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429073247a46b2267&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>由辉瑞一手孵化，现在拟被默克收购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n由辉瑞一手孵化，现在拟被默克收购\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-28 09:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429073247a46b2267&s=b><strong>生物制药小编</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>不出意外，SpringWorks Therapeutics要被德国默克收购了。近日，两家公司已就收购价上达成一致，德国默克将以每股47美元收购SpringWorks，收购总价约为35亿美元，如果后续收购工作顺利，该交易将在下周内完成。由辉瑞一手孵化SpringWorks成立于2017年，是一家专注于癌症和罕见病药物开发的Biotech公司，2019年在纳斯达克证券交易所上市。SpringWorks...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429073247a46b2267&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0965508806.USD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429073247a46b2267&s=b","article_id":"2531294179","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429073247a46b2267&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2531294179","pubTimestamp":1745803200,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"不出意外，SpringWorks Therapeutics要被德国默克收购了。近日，两家公司已就收购价上达成一致，德国默克将以每股47美元收购SpringWorks，收购总价约为35亿美元，如果后续收购工作顺利，该交易将在下周内完成。由辉瑞一手孵化SpringWorks成立于2017年，是一家专注于癌症和罕见病药物开发的Biotech公司，2019年在纳斯达克证券交易所上市。SpringWorks可以算是由辉瑞一手孵化，SpringWorks的创始人是辉瑞的前研发主管Lara S. Sullivan。这两款药物现在都成功批准上市。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4581":"高盛持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","BK4516":"特朗普概念","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","BK4592":"伊斯兰概念","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","PFE":"辉瑞","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4550":"红杉资本持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","MRK":"默沙东","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4007":"制药","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"Incubated by Pfizer, now planned to be acquired by Merck","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1,"PFE":0.9},"content_text":"不出意外，SpringWorks Therapeutics要被德国默克收购了。近日，两家公司已就收购价上达成一致，德国默克将以每股47美元收购SpringWorks，收购总价约为35亿美元，如果后续收购工作顺利，该交易将在下周内完成。由辉瑞一手孵化SpringWorks成立于2017年，是一家专注于癌症和罕见病药物开发的Biotech公司，2019年在纳斯达克证券交易所上市。SpringWorks可以算是由辉瑞一手孵化，SpringWorks的创始人是辉瑞的前研发主管Lara S. Sullivan。成立之初，SpringWorks便获得了辉瑞的四条研发管线的授权，其中就包括目前两个已经获批上市的药物nirogacestat和mirdametinib，另外，SpringWorks还获得了辉瑞的风险投资，2017年和2019年，辉瑞分别参与了SpringWorks A轮和B轮融资。这两款药物现在都成功批准上市。Nircgacestat于2023年11月27日获FDA批准上市（Ogsiveo），用于需要全身治疗的进展性纤维瘤成年患者，是该类患者群体的全球首个获批治疗药物。Mirdametinib于2025年2月11日获FDA批准上市，用于治疗患有1型神经纤维瘤病相关丛状神经纤维瘤 (NF1-PN)的儿童和成人患者，其也是这类患者群体的全球首个获批治疗药物。鲜少出手的默克相比于其他大药企，德国默克近几年对于并购交易看起来兴致缺缺，收购Springworks是其近几年来来最大的并购交易之一。在公司医药健康领域，特别制药业务，公司也确实遇到了不少挑战，其核心产品Mavenclad即将面临专利到期，并且销售增长也在减缓，2024年销售额同比仅增长12.3%。管线研发方面，德国默克也遭遇了不少挫折。2023年12月，德国默克宣布其BTK抑制剂evobrutinib治疗复发多发性硬化症的两项III期EVOLUTIONRMS 1、EVOLUTIONRMS 2临床相继宣告失败，最终被公司终止开发。2024年6月，独立数据监测委员会在对其IAP抑制剂Xevinapant的III期临床试验TrilynX（治疗未切除的局部晚期头颈部鳞状细胞癌)进行中期分析后发现不太可能达到延长无事件生存期（EFS）的主要终点目标，然后公司随即也终止了继续开发。通过收购Springworks，其可以直接获得两款现成的上市产品。Ogsiveo上市之后的销售表现也不错，第一年（2024年）的销售额便达到了1.72亿美元。目前，Springworks开发了卵巢颗粒细胞瘤、复发/难治性骨髓瘤等适应症。据摩根大通分析师预测，Ogsiveo的销售峰值有望达到10亿美元。现在又有了Mirdametinib的获批，加上公司财务状况良好（截至2024年12月31日，公司现金、现金等价物以及有价证券约4.6亿美元），SpringWorks已经有了盈利的规划—2026年。对于德国默克而言，如果该交易达成，SpringWorks也是立马就能为公司贡献营收。除了两款上市药物之外，SpringWorks还有三条在研管线。其中口服RAF抑制剂brimarafenib目前与百济合作开发，目前处于临床Ⅰ期阶段，用于治疗MAPK突变实体瘤。TEAD抑制剂SW-682临床Ⅰ期阶段，被开发用于治疗具有 Hippo 通路突变的晚期实体瘤。公司还有一款处于临床Ⅰ期的TEAD抑制剂SW-682，被开发用于治疗Hippo通路突变的晚期实体瘤。以及一款临床前的PP2A激动剂SW-3431，用于治疗罕见子宫癌。参考出处：https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-reports-fourth-quarter-and-full-year-4","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531294179","isCrawlerRequest":true}